# NovaBridge Biosciences: overview

NBP · Nasdaq · CIK 1778016 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nbp.md) · [Financials](/companies/nbp/financials.md) · [Filings](/companies/nbp/filings.md) · [Insiders](/companies/nbp/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

Not reported.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [13.8](/filings/0001193125-22-133550.md) | [(1.6)](/filings/0000950170-25-050344.md) | [0.6](/filings/0001778016-26-000002.md) | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | [3422.2%](/filings/0000950170-25-050344.md) | [(11395.1%)](/filings/0001778016-26-000002.md) | not reported | not reported |
| Net margin | % | [(2648.7%)](/filings/0001193125-22-133550.md) | [23923.5%](/filings/0000950170-25-050344.md) | [(32868.5%)](/filings/0001778016-26-000002.md) | not reported | not reported |
| Diluted EPS | $ per share | [(2.09)](/filings/0001193125-22-133550.md) | [(1.96)](/filings/0000950170-25-050344.md) | [(1.09)](/filings/0001778016-26-000002.md) | [(0.12)](/filings/0001778016-26-000002.md) | [(0.21)](/filings/0001778016-26-000002.md) |
| Free cash flow | $m | [(157)](/filings/0001193125-22-133550.md) | [(162)](/filings/0001104659-23-053462.md) | [(184)](/filings/0001104659-24-054452.md) | [(52.7)](/filings/0001778016-26-000002.md) | [(20.6)](/filings/0001778016-26-000002.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nbp/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $14.8m | 6,032,650 |  | Not compared |
| [HHLR ADVISORS, LTD.](/funds/1762304.md) | 2026-06-30 | $11.7m | 5,980,568 |  | Unchanged |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $7.1m | 3,653,228 |  | Reduced −184,970 |
| [AIHC Capital Management Ltd](/funds/2103725.md) | 2026-06-30 | $5.6m | 2,878,033 |  | Added +615,100 |
| [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $3.9m | 2,004,739 |  | Reduced −995,261 |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $2.4m | 1,231,946 |  | New +1,231,946 |
| [Candriam S.C.A.](/funds/1537014.md) | 2026-06-30 | $2.2m | 1,132,563 |  | Unchanged |
| [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $1.9m | 1,000,000 |  | Unchanged |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $1.7m | 851,348 |  | New +851,348 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.5m | 758,226 |  | Added +485,814 |

## Recent filings

[All 327 filings](/companies/nbp/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-28 | 07:00 ET | [6-K](/filings/0001193125-26-435065.md) | Report of a foreign private issuer, period 2026-10-28 | 0001193125-26-435065 |
| 2026-10-26 | 06:01 ET | [6-K](/filings/0001193125-26-430974.md) | Report of a foreign private issuer, period 2026-10-25 | 0001193125-26-430974 |
| 2026-10-23 | 09:15 ET | [6-K](/filings/0001193125-26-429548.md) | Report of a foreign private issuer, period 2026-10-23 | 0001193125-26-429548 |
| 2026-10-13 | 07:00 ET | [6-K](/filings/0001193125-26-419669.md) | Report of a foreign private issuer, period 2026-10-13 | 0001193125-26-419669 |
| 2026-09-08 | 07:00 ET | [6-K](/filings/0001193125-26-384356.md) | Report of a foreign private issuer, period 2026-09-08 | 0001193125-26-384356 |
| 2026-09-08 | 07:00 ET | [6-K](/filings/0001193125-26-384355.md) | Report of a foreign private issuer, period 2026-09-08 | 0001193125-26-384355 |
| 2026-08-20 | 07:00 ET | [6-K](/filings/0001193125-26-357819.md) | Report of a foreign private issuer, period 2026-06-30 | 0001193125-26-357819 |
| 2026-08-20 | 07:00 ET | [6-K](/filings/0001193125-26-357817.md) | Report of a foreign private issuer, period 2026-08-20 | 0001193125-26-357817 |
| 2026-07-24 | 17:05 ET | [6-K](/filings/0001193125-26-316242.md) | Report of a foreign private issuer, period 2026-07-24 | 0001193125-26-316242 |
| 2026-07-17 | 06:02 ET | [6-K](/filings/0001193125-26-306688.md) | Report of a foreign private issuer, period 2026-07-13 | 0001193125-26-306688 |

## Latest annual report

[Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001778016-26-000002.md), filed Apr 7, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1778016
- Tickers: NBP
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: E9
- Filer category: Non-accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 07:01 ET. No prices; not investment advice.